ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients

Zhang, Qi; Liang, Jinlin; Yin, Junhua; Jiang, Yiyue; Yu, Ning; Liao, Xingmei; Zhao, Siru; Wu, Leyuan; Fan, Rong*南方医科大学
Journal of Medical Virology2022-11DOI: 10.1002/jmv.27977
2被引5阅读
引用收藏
分享

摘要

The impact of long-term nucleos(t)ide analogs treatment on host metabolism is a concern. Hence, we conducted this study to compare the effect of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on metabolic parameters among chronic hepatitis B (CHB) patients. In this real-life retrospective study, 2030 CHB outpatients treated with ETV or TDF at Nanfang Hospital, China, were included. For treatment-naive patients, pretreatment and semiannual metabolic parameters were collected. For treatment-experienced patients, metabolic parameters were collected at the first visit. Propensity score matching (PSM) was used to balance the effects of potential confounding factors. Among 122 treatment-naive patients and 1908 treatment-experienced patients, ETV-treated patients were older with a higher percentage of metabolic syndrome. After PSM, the characteristics were comparable between the two groups. For treatment-naive patients, four lipid parameters, including total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein, and triglyceride levels showed a decreasing trend during the 42-month TDF treatment, while they remained relatively stable or increased during ETV treatment. At Month 30, the levels of TC and LDL among TDF-treated patients were significantly lower than those among ETV-treated patients (TC: 4.7 mmol/L vs. 3.9 mmol/L, p = 0.004; LDL: 3.0 mmol/L vs. 2.4 mmol/L, p = 0.009). For treatment-experienced patients, we also observed lower levels of lipid parameters in patients with different durations of TDF treatment. The levels of glucose and uric acid were similar among ETV- and TDF-treated patients. TDF has a lipid-lowering effect in CHB patients, which provides a basis for the selection of antiviral drugs for aging CHB patients.

学科与关键词

关键词
chronic hepatitis Bentecavirlipid panelmetabolic parameterstenofovir disoproxil fumarate
相关
加载中…
  • Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis
    Ke Weixia; Liu Li; Zhang Chi; Ye Xiaohua; Gao Yanhui; Zhou Shudong; Yang Yi*PLoS ONE, 2014, 9(6): e98865.
  • Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
    Liang, Xieer; Xie, Qing; Shang, Jia; Tang, Hong; Xu, Min; Meng, Qinghua; Zhang, Jiming; Gao, Pujun; Sheng, Jifang; Wang, Hao; Jia, Jidong; Wang, Guiqiang; Wu, Shunquan; Ping, Jingna; Hou, Jinlin*Journal of Gastroenterology and Hepatology, 2022, 37(3): 471-479.
  • Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B
    Liao, Xingmei; Fan, Yujie; Zhong, Chunxiu; Zhao, Siru; Guo, Liangxu; Tan, Wenjuan; Yin, Junhua; Fan, Rong*BMC INFECTIOUS DISEASES, 2023, 23(1): 843.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Medical Virology
发表日期
2022-11
卷期
第 94 卷, 第 11 期
页码
5465-5474
DOI
10.1002/jmv.27977
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
National Nature Science Foundation of China

作者

  • Z

    Zhang, Qi (第一作者)

  • L

    Liang, Jinlin

查看全部 9 位作者收起作者
  • Y

    Yin, Junhua

  • J

    Jiang, Yiyue

  • Y

    Yu, Ning

  • L

    Liao, Xingmei

  • Z

    Zhao, Siru

  • W

    Wu, Leyuan

  • F

    Fan, Rong (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417